CN117500500A - 治疗自身免疫性血液病的方法 - Google Patents

治疗自身免疫性血液病的方法 Download PDF

Info

Publication number
CN117500500A
CN117500500A CN202280043007.4A CN202280043007A CN117500500A CN 117500500 A CN117500500 A CN 117500500A CN 202280043007 A CN202280043007 A CN 202280043007A CN 117500500 A CN117500500 A CN 117500500A
Authority
CN
China
Prior art keywords
subject
patient
weeks
hydrochloride
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280043007.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·S·舒巴特韦伦西克
G·容格
T·霍布罗
R·乔拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN117500500A publication Critical patent/CN117500500A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280043007.4A 2021-06-18 2022-06-17 治疗自身免疫性血液病的方法 Pending CN117500500A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163212465P 2021-06-18 2021-06-18
US63/212,465 2021-06-18
PCT/IB2022/055639 WO2022264101A1 (en) 2021-06-18 2022-06-17 Method of treating an autoimmune hematological disorder

Publications (1)

Publication Number Publication Date
CN117500500A true CN117500500A (zh) 2024-02-02

Family

ID=82595001

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280043007.4A Pending CN117500500A (zh) 2021-06-18 2022-06-17 治疗自身免疫性血液病的方法

Country Status (5)

Country Link
US (1) US20240277689A1 (https=)
EP (1) EP4355329A1 (https=)
JP (1) JP2024522769A (https=)
CN (1) CN117500500A (https=)
WO (1) WO2022264101A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021414253B2 (en) * 2020-12-30 2024-05-16 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Series of piperidine-substituted benzoic acid compounds, and use thereof
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
WO2025148628A1 (zh) * 2024-01-10 2025-07-17 河北以岭医药研究院有限公司 哌啶基吲哚衍生物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN120208923A (zh) 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式

Also Published As

Publication number Publication date
JP2024522769A (ja) 2024-06-21
WO2022264101A1 (en) 2022-12-22
US20240277689A1 (en) 2024-08-22
EP4355329A1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
US20240025975A1 (en) Administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
JP2025146943A (ja) 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
CN117500500A (zh) 治疗自身免疫性血液病的方法
JP7823117B2 (ja) 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与
EP3288586A1 (en) Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
TW201718014A (zh) C5抑制劑於移植相關微血管病之用途
JP2019530728A (ja) 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
JP2025148495A (ja) Ｂ因子阻害剤の使用方法
US20240238266A1 (en) Iptacopan for the treatment of atypical hemolytic uremic syndrome
TW202140012A (zh) 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
AU2020341580A1 (en) Use of calcineurin inhibitor free CTLA4-Ig + anti-IL6/IL6R for long term immunosuppression in solid organ transplant recipients
RU2822664C2 (ru) ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС)
JP2025535457A (ja) 原発性膜性腎症を治療するための方法
WO2025019307A2 (en) Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
TW202545563A (zh) 用於治療iga腎病(igan)之抗c5抗體的劑量與投予
WO2025172910A1 (en) Factor b inhibitors for treatment of anca-associated vasculitis
TW202539668A (zh) 使用索樂匹尼布處置免疫性血小板減少症的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination